Keyuan Pharma
Shandong, Fujian, China, Asia
Overview
Keyuan Pharmaceutical is a pharmaceutical company that engages in the manufacture of pharmaceuticals. Tablets, fluids, ointments, and injectables are among their offerings. Its goal is to improve people's lives by enabling them to achieve more, feel better, and live longer. They have technological machinery, skilled and motivated individuals, and management systems that can handle both quantity and quality of work. They are looking for new ways to improve their performance, raise their integrity to a level of excellence, implement their initiatives, and achieve their goals.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 0
Sector focus
- Biotechnology
- Medical
- Pharmaceutical
Investment portfolio
- Drug Farm
Participated · Series D · Jul 2026
Drug Farm leverages proprietary platforms—IDInVivo+ (which integrates genetics and AI to identify and validate targets in living systems) and MedChem5 (used to advance first-in-class candidates)—to discover and progress drug candidates. The company is developing treatments across rare disease, cardiovascular, kidney, metabolic, autoimmune, and infectious disease indications. Its lead program, DF-003, is a first-in-class ALPK1 inhibitor that has shown clinical improvement in an ongoing Phase 1b study for ROSAH syndrome and is positioned to enter a Phase 3 trial; DF-003 has received multiple FDA designations including Fast Track and Orphan Drug. Another key program, DF-006, is an orally administered ALPK1 agonist immunomodulator that completed single and multiple ascending dose evaluations in healthy volunteers and in virologically suppressed HBeAg-negative chronic hepatitis B patients, showing encouraging anti-HBV activity. Drug Farm has entered a clinical collaboration with Xiamen Amoytop Biotech to develop DF-006 for hepatitis B and hepatocellular carcinoma. The recent $55 million Series D first closing provides capital to advance pivotal trials, global development, regulatory activities, and R&D expansion.
Team
No current team members are available.